Cover Image
市場調查報告書

EpiCast Report:類風溼性關節炎──流行病學的預測

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 320340
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:類風溼性關節炎──流行病學的預測 EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025
出版日期: 2017年01月01日 內容資訊: 英文 62 Pages
簡介

類風溼性關節炎(RA)為自體免疫疾病的一種,引起關節發炎。類類風溼性關節炎發病時,人體的免疫系統會攻擊關節內側,產生發炎反應。並且引起在青年時的死亡和身體障礙,生活品質(QoL)降低的問題。全球主要8個國家的類風溼性關節炎的患者數,2013年階段達到12,901,398人,預計2023年達到14,896,291人,其間的年複合成長率(CAGR)估計為1.55%。還有在主要10個國家受診斷的患者數,2013年估計為7,328,399人,預計2023年達到8,518,398人。

本報告提供全球主要國家的類風溼性關節炎(RA)的發病情形與今後預測相關分析、疾病的特徵、及目前患病者的發病情形、今後10年的患病數量的預測值等調查評估。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
    • 澳洲
    • 中國
    • 印度
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法:類風溼性關節炎的患病者總數
    • 預測的前提條件與手法:類風溼性關節炎已診斷的患病人數
  • 類風溼性關節炎的流行病學的預測(今後11年份)
    • 類風溼性關節炎的患病者總數
    • 類風溼性關節炎的患病者總數:各年齡
    • 類風溼性關節炎的患病者總數:男女
    • 類風溼性關節炎已診斷的患病人數
    • 類風溼性關節炎的患病人數(已調整年齡)
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER145-16

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body (CDC, 2015; Mayo Clinic, 2016). In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response (CDC, 2015). The disease can lead to premature mortality, disability, and decreased quality of life.

In the 8MM, epidemiologists forecast that the diagnosed incident cases of RA will increase from 195,592 cases in 2015 to 216,467 cases in 2025, at an Annual Growth Rate (AGR) of 1.07%. The US will have the highest number of diagnosed incident cases of RA among the 8MM throughout the forecast period, while Spain will have the lowest.

Epidemiologists forecast that the diagnosed prevalent cases of RA will increase from 4,354,194 cases in 2015 to 4,931,572 cases in 2025, at an AGR of 1.33%. The US will have the highest number of diagnosed prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

The report “EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of RA in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, and total prevalent cases of RA segmented by age and sex in these eight markets. The diagnosed prevalent cases of RA are further segmented by severity in the 8 MM for the forecast period.

Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 6
  • 1.2 List of Figures 7

2 Epidemiology 8

  • 2.1 Disease Background 8
  • 2.2 Risk Factors and Comorbidities 9
  • 2.3 Global Trends 9
    • 2.3.1 Diagnosed Incidence 11
    • 2.3.2 Prevalence 12
  • 2.4 Forecast Methodology 14
    • 2.4.1 Sources Used 14
    • 2.4.2 Forecast Assumptions and Methods 18
    • 2.4.3 Sources Not Used 28
  • 2.5 Epidemiological Forecast for RA (2015-2025) 28
    • 2.5.1 Diagnosed Incident Cases 28
    • 2.5.2 Diagnosed Prevalent Cases 35
    • 2.5.3 Total Prevalent Cases 43
  • 2.6 Discussion 50
    • 2.6.1 Epidemiological Forecast Insight 50
    • 2.6.2 Limitations of the Analysis 51
    • 2.6.3 Strengths of the Analysis 52

3 Appendix 53

  • 3.1 Bibliography 53
  • 3.2 Physicians and Specialists Included in this Study 56
  • 3.3 About the Authors 58
    • 3.3.1 Epidemiologist 58
    • 3.3.2 Reviewers 58
    • 3.3.3 Global Director of Therapy Analysis and Epidemiology 59
  • 3.4 About GlobalData 60
  • 3.5 About EpiCast 60
  • 3.6 Disclaimer 61

List of Tables

  • Table 1: Risk Factors and Comorbidities of RA 9
  • Table 2: 1987 ACR Diagnostic Criteria for RA 10
  • Table 3: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA 15
  • Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA 16
  • Table 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA 17
  • Table 6: 8MM, Sources Used to Forecast Severity Segmentation of the Diagnosed Prevalent Cases of RA 18
  • Table 7: 8MM, Sources Not Used in the Epidemiological Analysis of RA 28
  • Table 8: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 29
  • Table 9: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N (Row %), 2015 31
  • Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N (Row %), 2015 33
  • Table 11: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 36
  • Table 12: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N (Row %), 2015 38
  • Table 13: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015 40
  • Table 14: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 44
  • Table 15: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2015 46
  • Table 16: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015 48
  • Table 17: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016 57

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, 2015-2025 30
  • Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N, 2015 32
  • Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N, 2015 34
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RA, Ages ≥18 Years, Cases per 100,000 Population, 2015 35
  • Figure 5: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 37
  • Figure 6: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N, 2015 39
  • Figure 7: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N, 2015 41
  • Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA, Ages ≥18 Years, %, 2015 42
  • Figure 9: 8MM, Diagnosed Prevalent Cases of RA by Severity, Both Sexes, Ages ≥18 Years, N, 2015 43
  • Figure 10: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 45
  • Figure 11: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2015 47
  • Figure 12: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2015 49
  • Figure 13: 8MM, Age-Standardized Total Prevalence of RA, Ages ≥18 Years, N, 2015 50
Back to Top